SEMA4D/VEGF surface enhances endothelialization by diminished-glycolysis-mediated M2-like macrophage polarization

• Published in: Materials today bio 2023-12, Vol.23, p.100832-100832, Article 100832
• Main Authors: Cui, Yuanyuan, Jiang, Xiaomei, Yang, Maozhu, Yuan, Yinglin, Zhou, Zili, Gao, Xiang, Jia, Guiqing, Cao, Lvzhou, Li, Danni, Zhao, Yanshuang, Zhang, Xin, Zhao, Gaoping
• Format: Article
• Language: English
• Subjects: Endothelialization; Immunometabolism; M2-like macrophage phenotype; Semaphorin 4D (SEMA4D); Vascular endothelial growth factor (VEGF)
• ISSN: 2590-0064; 2590-0064
• DOI: 10.1016/j.mtbio.2023.100832

Cardiovascular disease remains the leading cause of death and morbidity worldwide. Inflammatory responses after percutaneous coronary intervention led to neoathrosclerosis and in-stent restenosis and thus increase the risk of adverse clinical outcomes. In this work, a metabolism reshaped surface is engineered, which combines the decreased glycolysis promoting, M2-like macrophage polarization, and rapid endothelialization property. Anionic heparin plays as a linker and mediates cationic SEMA4D and VEGF to graft electronically onto PLL surfaces. The system composed by anticoagulant heparin, immunoregulatory SEMA4D and angiogenic VEGF endows the scaffold with significant inhibition of platelets, fibrinogen and anti-thrombogenic properties, also noteworthy immunometabolism reprogram, anti-inflammation M2-like polarization and finally leading to rapid endothelializaiton performances. Our research indicates that the immunometabolism method can accurately reflect the immune state of modified surfaces. It is envisioned immunometabolism study will open an avenue to the surface engineering of vascular implants for better clinical outcomes. [Display omitted]